Terns Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TERN research report →
Companywww.ternspharma.com
Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH.
- CEO
- Amy L. Burroughs
- IPO
- 2021
- Employees
- 59
- HQ
- Foster City, CA, US
Price Chart
Valuation
- Market Cap
- $4.77B
- P/E
- -51.28
- P/S
- 0.00
- P/B
- 4.90
- EV/EBITDA
- -38.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.02%
- ROIC
- -10.91%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-96,207,000 · -8.28%
- EPS
- $-1.03 · 8.04%
- Op Income
- $-110,124,000
- FCF YoY
- -17.30%
Performance & Tape
- 52W High
- $53.19
- 52W Low
- $2.65
- 50D MA
- $50.15
- 200D MA
- $29.48
- Beta
- -0.38
- Avg Volume
- 5.92M
Get TickerSpark's AI analysis on TERN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 5, 26 | Azelby Robert | sell | 90,000 |
| May 5, 26 | Azelby Robert | sell | 1,697 |
| May 5, 26 | Turner Heather D | sell | 45,000 |
| May 5, 26 | Turner Heather D | sell | 64,000 |
| May 5, 26 | Turner Heather D | sell | 1,697 |
| May 5, 26 | Tripuraneni Radhika | sell | 64,000 |
| May 5, 26 | Tripuraneni Radhika | sell | 45,000 |
| May 5, 26 | Tripuraneni Radhika | sell | 10,657 |
| May 5, 26 | Tripuraneni Radhika | sell | 4,676 |
| May 5, 26 | Tripuraneni Radhika | sell | 32,000 |
Our TERN Coverage
We haven't published any research on TERN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TERN Report →